FDA accepts BioXcel’s at-home agitation drug application for review

BioXcel Therapeutics (NASDAQ:BTAI) announced that the U.S. Food and Drug Administration has formally accepted a supplemental New Drug Application for its lead neuropsychiatric drug, providing a clear regulatory catalyst as the company manages tightening capital constraints.

The Connecticut-based developer stated that the regulatory agency accepted the filing for the at-home use of IGALMI (dexmedetomidine) sublingual film for the acute treatment of agitation associated with bipolar disorders or schizophrenia.

The FDA assigned a Prescription Drug User Fee Act action date of November 14, 2026, advancing a key commercial expansion strategy aimed at moving administration outside traditional institutional care settings.

The regulatory progression arrives alongside an ongoing review of the company's asset footprint.

Management confirmed it has engaged investment banking firm MTS Health Partners to evaluate value-maximizing strategic alternatives specifically for the IGALMI commercial franchise, including potential partnerships, licensing, or structural divestitures.

Simultaneously, resources are being prioritized to advance the late-stage development of its BXCL501 platform, including the ongoing TRANQUILITY Phase 3 clinical trial evaluating the therapy for acute agitation associated with Alzheimer’s dementia.

Financially, the pre-revenue enterprise continues to run a substantial operational deficit.

BioXcel reported total IGALMI net product revenue of $206,000 for the three months ended March 31, 2026, up slightly from $168,000 in the first quarter of the prior year.

Driven by ongoing corporate overhead and late-stage pipeline investments, the company recorded an operating loss of $10.2 million and a consolidated net loss of $12.7 million for the quarter, compared to a net loss of $7.3 million in the opening quarter of 2025.

BioXcel concluded the first quarter with $17.2 million in cash and cash equivalents.

In its regulatory disclosures, management acknowledged that its current capital stack, paired with recurring operational demands, continues to raise substantial doubt regarding the company’s ability to continue as a going concern, emphasizing the immediate need to secure additional financing options or strategic execution before the end of the fiscal year.